Psychedelics

Answer a quick question on psychedelics!

Learn more about the potential of MDMA-assisted psychotherapy.

Answer a quick question on psychedelics!

Answer a quick question on psychedelics!

Learning to use a psychedelic agent can be challenging when the protocols are not defined. Here’s how a psychiatrist got started.

According to the chief medical officer of MindMed, it is time to look past the history of LSD.

Generalized anxiety disorder: has it been sidelined by MDD? MM-120 is a new treatment under investigation for this disorder, making waves.

A psychiatrist explores ketamine-assisted psychotherapy in this ongoing series.

Here are highlights from the week in Psychiatric Times.

Psychedelics: it is time to integrate this treatment option into clinical care while holding fast to the principles of medical ethics.

Study results suggest the potential for a scalable, single-dose treatment approach.

Lykos Therapeutics recently received priority review of MDMA-assisted therapy for patients with PTSD. Check out the latest research update here!

The short-acting psychedelic, BPL-003, resulted in rapid, durable depression symptom reduction in patients with TRD.

This may be a pivotal moment in the history of psychedelics...

From mild cognitive impairment and serotonin system degeneration to an update on pimavanserin for negative symptoms of schizophrenia, here are highlights from the week in Psychiatric Times.

As we enter the second coming of psychedelics popularity, H. Steven Moffic, MD, looks ahead to their third coming. Will it be similar to that of Dune?

The US Food and Drug Administration has granted breakthrough designation to MindMed’s lysergide d-tartrate program (MM-120) for the treatment of generalized anxiety disorder.

This trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of VLS-01 compared with intravenous DMT for treatment-resistant depression.

Here are some updates from the world of psychiatry throughout the month of February.

From psychotherapy vs pharmacotherapy for depression in heart failure to an update on the 2024 medication pipeline for antidepressants and ADHD treatments, here are highlights from the week in Psychiatric Times.

The treatment's PDUFA date is set for August 11, 2024.

From substance use disorders in physicians to new research on the efficacy of MDMA-assisted therapy for PTSD, here are highlights from the week in Psychiatric Times.

Here are some updates from the world of psychiatry throughout the month of December.

Reviewing a year of CMEs in Psychiatric Times®

MAPS has submitted an NDA for MDMA-assisted therapy for patients with posttraumatic stress disorder.

From late-life treatment-resistant depression to the mental health benefits of gratitude, here are highlights from the week in Psychiatric Times.

Ketamine for anxiety? Researchers performed a systematic review and meta-analysis of ketamine’s anxiolytic effects.

What is new in research on psychedelics?

Here are some updates from the world of psychiatry throughout the month of October.